Status:
COMPLETED
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
Lead Sponsor:
Avid Radiopharmaceuticals
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological asse...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects are enrolled in this study if they:
- Met entrance criteria and were enrolled and imaged in trial 18F-AV-45-A07 (NCT00857415)
- Gave informed consent for the 18F-AV-45-A07 (NCT00857415) study procedures and brain donation consistent with the legal requirements of the State in which they are enrolled and the State in which they die
- Consent to participate in the 18F-AV-45-A16 (NCT01447719) extension protocol, if required by the IRB
- Reconfirm their consent to a research brain autopsy, if required by the IRB.
Exclusion
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT01447719
Start Date
March 1 2010
End Date
July 1 2011
Last Update
March 21 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States, 85006
2
Research Site
Sun City, Arizona, United States, 85351
3
Research Site
Little Rock, Arkansas, United States, 72211
4
Research Site
Irvine, California, United States, 92697